Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction by Enriqueta Felip, Paolo Nuciforo, Elena Garralda, Joan Frigola, Ramon Amat, Garazi Serna, Francesco Grussu, Kinga Bernatowicz, Olivia Prior, Marta Ligero, Christina Zatse, Rodrigo Toledo, Manel Escobar, Raquel Perez-Lopez

Get full text

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours by Michael Smith, Aung Naing, Todd Bauer, Kyriakos P Papadopoulos, Osama Rahma, Elena Garralda, Glenn J Hanna, Michael J Pishvaian, Xuejun Chen, Sven Gogov, Omar Saavedra, Howard Kallender, LuLu Cheng, Emil Kuriakose

Get full text

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial by Mrinal Gounder, Melissa Johnson, Rebecca S. Heist, Geoffrey I. Shapiro, Sophie Postel-Vinay, Frederick H. Wilson, Elena Garralda, Gerburg Wulf, Caroline Almon, Salah Nabhan, Elia Aguado-Fraile, Peng He, Mathilde Romagnoli, Mohammad Hossain, Rohini Narayanaswamy, Amel Sadou-Dubourgnoux, Michael Cooper, Vasileios Askoxylakis, Howard A. Burris, Josep Tabernero

Get full text

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies by Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo De Braud

Get full text